Pliant Therapeutics
PLRX
125 hedge funds and large institutions have $861M invested in Pliant Therapeutics in 2022 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 42 increasing their positions, 31 reducing their positions, and 20 closing their positions.
85% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 20
83% more call options, than puts
Call options by funds: $4.53M | Put options by funds: $2.48M
35% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 31
14% more funds holding
Funds holding: 110 → 125 (+15)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
1.55% less ownership
Funds ownership: 93.23% → 91.68% (-1.6%)
7% less capital invested
Capital invested by funds: $925M → $861M (-$63.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$19.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$12M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$11.1M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.58M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$41.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$35.4M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$13.2M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$5.7M |
| 5 |
CA
CHI Advisors
New York
|
-$5.01M |
PLRX Hedge Fund Activity: Q4 2022 in Review
125 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q4 2022, worth a combined $861M — down 6.9% from $925M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new PLRX positions and 20 closed out — a net gain of 17 holders — while 42 added to existing stakes and 31 trimmed.
The largest buyer was Casdin Capital, adding an estimated $19.3M. The largest seller was TRV GP III, cutting an estimated $41.8M.
- 125 institutional investors held Pliant Therapeutics (PLRX) as of Q4 2022, up from 110 in Q3 2022.
- Funds reported $861M of Pliant Therapeutics stock for Q4 2022, down 6.9% quarter-over-quarter.
- 37 funds opened new Pliant Therapeutics positions in Q4 2022 and 20 closed out, a net change of +17 holders.
- The largest Pliant Therapeutics buyer in Q4 2022 was Casdin Capital, an estimated $19.3M added.
- The largest Pliant Therapeutics seller in Q4 2022 was TRV GP III, an estimated $41.8M sold.
Based on aggregated 13F filings for Q4 2022.